Patents Examined by Carol E. Bidwell
-
Patent number: 5470712Abstract: The present invention relates to antigenic proteins specific to Borrelia burgdorferi which have a molecular weight of 28 kDa or 39 kDa as determined by SDS-PAGE and are reactivity with Lyme borreliosis serum or fragments thereof and to the corresponding DNA. The proteins, especially the 39 kDa proteins (.alpha. and .beta.) can be used to diagnosis mammals previously or currently infected with the Lyme borreliosis causing agent.Type: GrantFiled: February 19, 1993Date of Patent: November 28, 1995Inventors: Warren Simpson, T. G. Schwan
-
Patent number: 5459042Abstract: The invention relates methods of determining Entamoeba histolytica antigenic reference patterns of proteins recognized by sera from patients having amebic liver abscesses, patients having intestinal amebiasis and patients negative for any amebic disease and methods using these antigenic reference patterns for aiding in the differential diagnosis of a patient with amebic liver abscesses or intestinal ambiasis by detecting the presence of antibodies in a sample of human serum which bind to Entamoeba histolytica proteins identified in the antigenic reference patterns.Type: GrantFiled: October 20, 1993Date of Patent: October 17, 1995Inventor: Maria D. S. Flores de Castaneda
-
Patent number: 5441870Abstract: Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diagnosis and prognosis of Alzheimer's disease and other .beta.-amyloid-related diseases, while in vitro monitoring of such secretion from cultured cells may be monitored to identify inhibitors of .beta.-amyloid production. The .beta.APP fragment may be detected using antibodies and other specific binding substances which recognize a carboxy-terminal residue on the fragment.Type: GrantFiled: October 26, 1992Date of Patent: August 15, 1995Assignees: Athena Neurosciences, Inc., Eli Lilly and CompanyInventors: Peter A. Seubert, Dale B. Schenk, Lawrence C. Fritz
-
Patent number: 5434050Abstract: The present invention provides: a labelled .beta.-amyloid peptide of active fragment; a composition including the labelled .beta.-amyloid peptide or active fragment thereof and a pharmaceutical carrier; a method for labelling the .beta.-amyloid peptide or an active fragment thereof, and methods of using the labelled peptide or peptide fragment for detecting or monitoring Alzheimer's disease in a patient.Type: GrantFiled: August 13, 1991Date of Patent: July 18, 1995Assignees: Regents of the University of Minnesota, President & Fellows of Harvard CollegeInventors: John E. Maggio, Patrick W. Mantyh
-
Patent number: 5432057Abstract: An assay method and compositions are provided for determining the presence of an analyte in a sample. The analyte is a member of an immunological pair (mip) comprising ligand and receptor. By providing a first measurement surface capable of specifically binding a labelled reagent in an amount depending upon the presence of analyte in the sample and a second calibration surface capable of binding a second labeled reagent in a manner unaffected by the presence of analyte in the sample, calibration of individual tests can be accomplished simultaneously with the performance of the test itself. A signal producing system includes an enzyme, a catalyst usually bonded to a mip which defines the first labeled reagent for binding to the measurement surface and the same catalyst conjugated to a ligand capable of binding to the calibration surface. Preferably, both labeled reagents have the same composition and the calibration surface includes anti-(first catalyst).Type: GrantFiled: August 28, 1992Date of Patent: July 11, 1995Assignee: Syva CompanyInventors: David J. Litman, Edwin F. Ullman
-
Patent number: 5429952Abstract: In general, the invention features a method of marking a product for identification in which a low molecular weight hapten is associated with the product as a marker, where the hapten is non-deleterious to the product, inert with respect to the product, and not already associated with the product.Type: GrantFiled: August 20, 1993Date of Patent: July 4, 1995Assignee: Biocode, Inc.Inventors: Ronald C. Garner, Carl N. Martin, Michael J. Wraith, David W. Britton
-
Patent number: 5422244Abstract: The present invention is related generally to methods and compositions for identifying and quantitating particular .alpha.1-antichymotrypsin species in a biological sample. More particularly, the present invention is related to methods and compositions for detecting and measuring a brain .alpha.1-antichymotrypsin species that is produced in brain tissue of individuals having a neuropathological condition and which is detectable in accessible biological samples. The invention provides detection assays, such as sandwich binding assays, for detecting and quantitating brain .alpha.1-antichymotrypsin in a biological sample, such as blood, urine, cerebrospinal fluid, or tissue. These detection assays are useful for detecting and diagnosing neuropathological diseases and for identifying cells of a human central nervous system lineage, and for other medical applications. The invention also provides binding components, such as antibodies that bind to brain .alpha.Type: GrantFiled: May 5, 1992Date of Patent: June 6, 1995Assignee: Athena Neurosciences, Inc.Inventors: Kelly Johnson-Wood, Dale Schenk
-
Patent number: 5420047Abstract: Immunodiagnostic tests in which enzymes or antibodies are bound to porous carrier materials can be carried out by employing as porous carrier materials macroporous polymer membranes which are prepared by(a) dispersing an insoluble filler in a solution which contains at least two incompatible polymers in amounts which lead to phase separation in the solution, resulting in a homogeneous casting solution, and(b) applying this solution to a support and carrying out a precipitation coagulation.Type: GrantFiled: November 12, 1993Date of Patent: May 30, 1995Assignee: Bayer AktiengesellschaftInventors: Heinz-Dieter Brandt, Rolf Dhein, Karlheinz Hildenbrand, Ronald Stocker
-
Patent number: 5420014Abstract: The present invention contemplates a method for detecting contempory infection by H. pylori in a mammal comprising contacting a mucous secretion from said mammal with an antigen component from H. pylori for a time and under conditions sufficient for an IgG antibody in said mucous secretion specific to said antigen component to form a complex therewith and then subjecting said complex to a detecting means. Preferably, the antigen component is immobilized onto a solid support.Type: GrantFiled: April 30, 1992Date of Patent: May 30, 1995Assignee: Auspharm International Ltd.Inventors: Allan Cripps, Campbell Witt, Robert L. Clancy, Daniel Stiel
-
Patent number: 5418140Abstract: A method for rapid identification of Vibrio parahaemolyticus in a sample containing suspect colonies which includes the steps of:(i) coating latex particles with a solution of antibodies or antisera against outer membrane proteins of V. parahaemolyticus at an appropriate concentration to obtain a latex reagent, and(ii) mixing the sample with the latex reagent obtained in the (i) under conditions appropriate to complete agglutination; and a kit for accomplishing the method are disclosed.Type: GrantFiled: August 10, 1993Date of Patent: May 23, 1995Assignee: Food Industry Research and Development InstituteInventors: Tsung C. Chang, Hui C. Chen
-
Patent number: 5415994Abstract: The present invention provides devices, methods, and kits for treatment and detection of analytes requiring pretreatment in samples. One-step treatment and detection is possible utilizing the devices and methods of the present invention.Type: GrantFiled: August 2, 1993Date of Patent: May 16, 1995Assignee: Quidel CorporationInventors: Michael R. Imrich, John K. Zeis, Steven P. Miller, Allan D. Pronovost
-
Patent number: 5413912Abstract: There is disclosed an antigenic peptide that comprises at least 15 amino acids having the sequence Ala Glu Pro Lys X Ala Glu Pro Lys X Ala Glu Pro Lys X, wherein X is Pro or Ser. This peptide is useful in an ELISA assay to detect antibodies specific to T. cruzi infection and Chagas disease. This peptide is further useful in a vaccine composition for immunizing an individual to prevent Chagas disease upon exposure to T. cruzi.Type: GrantFiled: December 17, 1993Date of Patent: May 9, 1995Inventor: Steven G. Reed
-
Patent number: 5411867Abstract: A novel highly sensitive method for detection of the presence of total coliform and E. coli in water samples, food products, and seafood. The method employs new type of media having composition which allows an unequivocal detection of very small number of E. coli. The new low pH media which contains trimethylamine-N-oxide promote the growth of chlorine or food processing injured E. coli for their easier detection. The method for sole detection of E. coli in water, in food products and in seafood.Type: GrantFiled: August 12, 1993Date of Patent: May 2, 1995Assignee: The Regents of the University of CaliforniaInventors: George W. Chang, Rosalind A. Lum
-
Patent number: 5411865Abstract: A method for detecting anti-Leishmania parasite antibodies to a 230 kDa antigen present in Leishmania chagasi and Leishmania donovani is disclosed which comprises obtaining a sample from an individual, contacting the sample with a recombinant K39 repeat unit antigen comprising the amino acid sequence as shown in SEQ ID NO:3, and detecting the presence of anti-Leishmania parasite antibodies in the sample which bind to the recombinant K39 repeat unit antigen.Type: GrantFiled: January 15, 1993Date of Patent: May 2, 1995Assignee: Iasys CorporationInventor: Steven Reed
-
Patent number: 5405748Abstract: A simple immunoassay method is provided which distinguishes pathogenic from nonpathogenic forms Entamoeba histolytica in biological samples. This assay utilizes monoclonal antibody preparations which are specific for designated epitopes of the 170 kd subunit of the Gal/GalNAc lectin. When pathogenic forms, specifically, are to be detected, at least one antibody which is immunospecific for an epitope unique to the forms of the 170 kd lectin found in pathogenic strains is used in the assay. The invention further includes monoclonal antibodies which are immunospecific for epitopes 1-3 of the 170 kd subunit of the Gal/GalNAc lectin of either pathogenic or nonpathogenic forms and to monoclonal antibodies specifically immunoreactive with epitopes unique to nonpathogenic derived 170 kd subunit, as well as purified forms of the Gal/GalNAc lectin from both pathogenic and nonpathogenic forms.Type: GrantFiled: June 10, 1993Date of Patent: April 11, 1995Assignee: University of Virginia Patents FoundationInventors: William A. Petri, Jr., Jonathan I. Ravdin
-
Patent number: 5403718Abstract: The invention relates to novel antigens associated with Borrelia burgdorferi which are exported (or shed) in vivo and whose detection is a means of diagnosing Lyme disease. The antigens are extracellular membrane vesicles and other bioproducts including the major extracellular protein. The invention further provides antibodies, monoclonal and/or polyclonal, labeled and/or unlabeled, that react with the antigens. The invention relates to a method for immune capture of specific microorganisms for their subsequent cultivation. The invention is also directed to a method of diagnosing Lyme disease by detecting the antigens in a biological sample taken from a host using the antibodies in conventional immunoassay formats. The invention further relates to kits, for the diagnosis of Lyme disease, comprising the antibodies and ancillary reagents.Type: GrantFiled: August 11, 1992Date of Patent: April 4, 1995Inventors: David W. Dorward, Tom G. Schwan, Claude F. Garon
-
Patent number: 5401831Abstract: A method to prepare a monoclonal antibody (mAb) specifically immunoreactive with an epitope of the Gal/GalNAc lectin of a pathogenic or nonpathogenic E. histolytica, or the 70 kd subunit thereof, is provided. This method comprises culturing an immortalized cell line capable of secreting the mAbs, where the cell line is obtained by immortalizing antibody-producing cells from a mammal immunized with a purified 170 kd subunit, or with purified Gal/GalNAc lectin of a pathogenic E. histolytica. The supernatants of the cells are screened for the presence or absence of antibodies specific for the subunit or lectin from a pathogenic E. histolytica and from a pathogenic E. histolytica, so as to determine the pathogen/nonpathogen specificity of the monoclonal antibody. Antibodies produced by this method and epitopes with which they react on pathogenic and/or nonpathogenic E. histolytica also are disclosed.Type: GrantFiled: June 10, 1993Date of Patent: March 28, 1995Assignee: University of Virginia Patents FoundationInventors: William A. Petri, Jr., Jonathan I. Ravdin
-
Patent number: 5399485Abstract: The present invention relates to a method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an immunogenically specific determinant thereof in the subject. Also provided by the present invention is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier.Type: GrantFiled: January 17, 1992Date of Patent: March 21, 1995Assignee: United States of AmericaInventors: Russell L. Regnery, Burt E. Anderson
-
Patent number: 5399484Abstract: A method has been developed for determining microorganisms associated with periodontal diseases which is highly sensitive and shows very low background and cross-reactivity among various closely related antigens. Antigen is extracted at relatively high pH, and either before or immediately after extraction, the antigen-containing specimen is mixed with a blocking composition having at least about 0.2 weight percent of a non-immunoreactive blocking protein. The pH of the resulting mixture is kept high when contacted with the antibodies specific to the antigen of interest. The compositions and components needed for the assay can be supplied in a diagnostic test kit.Type: GrantFiled: October 8, 1991Date of Patent: March 21, 1995Assignee: Eastman Kodak CompanyInventors: Bradley P. Boyer, Paul B. Contestable, Brian A. Snyder
-
Patent number: 5399316Abstract: A sample solution is dripped on an injection region with a pipette. The sample solution immediately spreads in a reaction region by a capillary phenomenon. The sample solution is left for a predetermined period of time to bind a biological associated material in the sample solution with a specific affinity material bound on the inner surface of the reaction region. After the reaction, the outer surface portion of a support member is pushed against a reaction vessel main body to deform the support member, thereby bringing the sample solution into contact with a water absorbent member at a removal region. The sample solution is absorbed by the water absorbent member and is removed from the reaction region. A cleaning solution is dripped on the injection region in an appropriate amount to perform B/F separation and is allowed to spread in the reaction region. The cleaning solution is absorbed and removed by the water absorbent member. The biological associated material bound to the reaction region is assayed.Type: GrantFiled: March 3, 1993Date of Patent: March 21, 1995Assignee: Olympus Optical Co., Ltd.Inventor: Takashi Yamada